1. Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity
- Author
-
Chin-Wei Lin, Ming-Hung Tsai, Chung-Yi Wu, Chi-Huey Wong, Chia-Lin Chen, Che Ma, Jen-Chi Hsu, and Chia-Hung Wang
- Subjects
0301 basic medicine ,Glycan ,Glycosylation ,Stereochemistry ,Crystallography, X-Ray ,Protein Engineering ,Biochemistry ,Immunoglobulin G ,03 medical and health sciences ,chemistry.chemical_compound ,Polysaccharides ,Humans ,Antibody-dependent cell-mediated cytotoxicity ,Molecular Structure ,030102 biochemistry & molecular biology ,biology ,Effector ,Immunoglobulin Fc Fragments ,Antibody-Dependent Cell Cytotoxicity ,General Medicine ,N-Acetylneuraminic Acid ,Sialic acid ,030104 developmental biology ,chemistry ,Drug Design ,biology.protein ,Molecular Medicine ,N-Acetylneuraminic acid - Abstract
N-glycosylation on IgG modulates Fc conformation and effector functions. An IgG-Fc contains a human sialo-complex type (hSCT) glycan of biantennary structure with two α2,6-sialylations and without core-fucosylation is an optimized glycoform developed to enhance the antibody dependent cellular cytotoxicity (ADCC). hSCT modification not only enhances the binding affinity to Fc receptors in the presence of antigen but also in some cases provides gain-of-function effector activity. We used enzymatic glyco-engineering to prepare an IgG-Fc with homogeneous hSCT attached to each CH2 domain and solved its crystal structure. A compact form and an open form were observed in an asymmetric unit in the crystal. In the compact structure, the double glycan latches from the two hSCT chains stabilize the CH2 domains in a closed conformation. In the open structure, the terminal sialic acid (N-acetylneuraminic acid or NeuNAc) residue interacts through water-mediated hydrogen bonds with the D249-L251 helix, to modulate the pivot region of the CH2-CH3 interface. The double glycan latches and the sialic acid modulation may be mutually exclusive. This is the first crystal structure of glyco-engineered Fc with enhanced effector activities. This work provides insights into the relationship between the structural stability and effector functions affected by hSCT modification and the development of better antibodies for therapeutic applications.
- Published
- 2017